Fig. 1: Green fluorescent protein (GFP) gene expression carried by JCPyV virus-like particles (VLPs) in human orthotopic prostate tumors in mice. | Cancer Gene Therapy

Fig. 1: Green fluorescent protein (GFP) gene expression carried by JCPyV virus-like particles (VLPs) in human orthotopic prostate tumors in mice.

From: Inhibition of orthotopic castration-resistant prostate cancer growth and metastasis in mice by JC VLPs carrying a suicide gene driven by the PSA promoter

Fig. 1

A Murine model establishment of a human orthotopic prostate tumor. In human castration-resistant prostate cancer (CRPC), 22Rv1 cells were implanted into the anterior prostate lobe 6-week-old mice at densities of 1 × 105 or 1 × 106. The mice were euthanized on days 14, 21, and 28 to observe the orthotopic tumor sizes. B The administration process of PSAgfp-VLPs or VLPs. Eight days after 22Rv1 was implanted into the mouse prostate, PSAgfp-VLPs or VLPs were administered every two days via tail vein injection for a total of six times. C 22Rv1 was implanted into mice prostates and PSAgfp-VLPs or VLPs were administered. After 22 days, the orthotopic prostate tumor was removed, frozen sections were made, and GFP expression was observed under a fluorescent microscope. D The size of the orthotopic prostate tumor in mice with 22Rv1 cells after administration of PSAGFP-VLPs or VLPs. (Scale bar = 50 mm).

Back to article page